Cost-Utility Analysis of STN1013001, a Latanoprost Cationic Emulsion, versus Other Latanoprost Formulations (Latanoprost) in Open-Angle Glaucoma or Ocular Hypertension and Ocular Surface Disease in France

Lazzaro C., Van Steen C., Aptel F., Schweitzer C., Angelillo L.

2022
Journal of Ophthalmology

View publication

Therapeutic Area

Glaucoma

Affiliations

Studio di Economia Sanitaria, Milan, Italy; Santen GmbH, München, Germany; Department of Ophthalmology, University Hospital, CHU Grenoble-Alpes, Grenoble, France; CHU Bordeaux, Department of Ophthalmology, University of Bordeaux, Bordeaux, 33000, France; Inserm, Bordeaux Population Health Research Center, Team LEHA, UMR 1219, Bordeaux, 33000, France

Related Publications

Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial

Wang T.H.; Aung T.; Lu D.-W.; George R.; Senthil S.; Lu F.; Odani-Kawabata N.; Park K.H.

Efficacy and Safety of a Preservative-Free Latanoprost Cationic Emulsion in Patients with Open-Angle Glaucoma and Concurrent Ocular Surface Disease: A Randomized Phase 2 Study.

Bacharach, Jason; McLaurin, Eugene B.; Silverstein, Steven; Amrane, Mourad; Garrigue, Jean-Sebastien; Ismail, Dahlia; Flynn, William J.; Catiolanze Phase 2 study group

Assessment of Brain-Derived Neurotrophic Factor on Retinal Structure and Visual Function in Rodent Models of Optic Nerve Crush

Taniguchi T.; Sharif N.A.; Ota T.; Farjo R.A.; Rausch R.

View all Glaucoma publications